Therachon raises $60 million in mezzanine financing for rare disease drugs
The Basel, Switzerland-based biotech company plans to trial the drug in achondroplasia patients next year.
Inserm Transfert Initiative
The Basel, Switzerland-based biotech company plans to trial the drug in achondroplasia patients next year.